As a 30-year-old with multiple sclerosis who will start disease-modifying therapy, should I receive updated meningococcal (including MenB) and pneumococcal vaccinations despite having received them in childhood, and what other vaccines should I discuss with my primary care physician?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vaccination Recommendations for MS Patients Starting Disease-Modifying Therapy

Yes, you should receive updated meningococcal and pneumococcal vaccines before starting your DMT, even though you received childhood vaccines, because many disease-modifying therapies for MS significantly increase your risk of invasive infections and require enhanced vaccination protection.

Critical Meningococcal Vaccination Updates Needed

You already received MenB before college, but you need to verify your MenACWY (quadrivalent) vaccination status and timing. According to current ACIP guidelines, if you received your last MenACWY dose before age 16, you need a booster dose now at age 30 1. Standard adolescent vaccination schedules recommend boosters at age 16-18, and since you're starting immunosuppressive therapy, this becomes even more critical.

Specific Meningococcal Recommendations:

  • MenACWY: If your last dose was before age 16, get a single booster dose now 1
  • MenB: Your pre-college MenB series may need updating depending on which DMT you'll receive. For high-risk immunosuppressed patients, MenB boosters are recommended 1 year after primary series, then every 2-3 years 1

Important timing consideration: Ideally complete meningococcal vaccination at least 2 weeks before starting your DMT 2, 3. If treatment must start urgently, vaccinate immediately and consider antibiotic prophylaxis during the initial treatment period 4.

Pneumococcal Vaccination - Essential Update Required

You absolutely need pneumococcal vaccination now, regardless of childhood vaccines. The childhood pneumococcal series (PCV7 or PCV13) you received does not provide adequate protection for immunocompromised adults.

Recommended Pneumococcal Schedule:

  1. PCV13 or PCV15 first (if not previously received as adult)
  2. PPSV23 at least 8 weeks later 5
  3. Second PPSV23 dose 5 years after the first 5

This two-vaccine approach is specifically recommended for immunocompromised patients and provides broader serotype coverage than childhood vaccines alone.

Additional Essential Vaccines Before DMT

High Priority (Complete Before DMT Start):

  • Influenza vaccine (annually, every year regardless of DMT) 3, 6
  • Haemophilus influenzae type B (Hib) - Often overlooked but recommended for immunocompromised patients 2
  • Hepatitis B series (if not previously completed) - Important given infection risks on immunosuppression 7

Verify and Update if Needed:

  • MMR (Measles, Mumps, Rubella) - Check antibody titers; if non-immune, must vaccinate before DMT as this is a live vaccine contraindicated once immunosuppressed 3, 6
  • Varicella (chickenpox) - Same as MMR; check immunity and vaccinate before DMT if needed 3
  • Tdap - You mentioned being up-to-date, which is good; boosters every 10 years

Consider Based on Risk Factors:

  • Hepatitis A - If traveling or other risk factors
  • HPV - You received this, which is excellent
  • Shingles (Recombinant Zoster Vaccine/Shingrix) - Generally recommended age 50+, but consider earlier for immunosuppressed patients; this is an inactivated vaccine safe on DMTs 6

Critical Timing Principles

The type of DMT you'll receive dramatically affects vaccination strategy:

For B-cell Depleting Therapies (Ocrelizumab, Rituximab, Ofatumumab):

  • Complete ALL vaccinations at least 4-6 weeks before first infusion 6, 8
  • These drugs severely impair antibody responses to vaccines for 6-12+ months
  • Vaccination during treatment provides minimal protection 9, 6

For S1P Modulators (Fingolimod, Siponimod, Ozanimod):

  • Vaccinate at least 2 weeks before starting 2
  • Reduced but present vaccine responses on therapy
  • Inactivated vaccines can be given during treatment if necessary 6

For Other DMTs (Natalizumab, Dimethyl Fumarate, Teriflunomide):

  • Less impact on vaccine responses
  • Still preferable to vaccinate before starting when possible 6

For Cladribine:

  • Unique opportunity: can vaccinate effectively between treatment courses and after completion 6

Practical Implementation Strategy

Discuss this specific timeline with your PCP:

  1. Week 0: Blood work to check MMR, varicella immunity
  2. Week 1: Administer all inactivated vaccines that can be given simultaneously:
    • MenACWY (if needed)
    • MenB booster (if indicated by DMT type)
    • PCV13/PCV15
    • Hib
    • Influenza (if season appropriate)
    • Hepatitis B (start series if needed)
  3. Week 2-3: If MMR or varicella needed (live vaccines), administer at least 4 weeks before DMT start 2, 3
  4. Week 4+: Can safely start DMT
  5. Week 12: PPSV23 (8 weeks after PCV)

A recent real-world study demonstrated this approach is feasible, with median vaccination completion time of 27 days without delaying DMT initiation 2.

Common Pitfalls to Avoid

  • Don't assume childhood vaccines provide lifelong protection - Many wane, and immunosuppression increases infection risk
  • Don't delay vaccination "to see how the disease progresses" - Once on certain DMTs, vaccine responses are severely compromised 9, 6
  • Don't receive live vaccines after starting immunosuppressive DMTs - Contraindicated and potentially dangerous 3, 6
  • Don't skip annual influenza vaccination - Recommended regardless of DMT type 3

Safety Reassurance

Extensive evidence confirms vaccinations do not trigger MS relapses or worsen disease activity 9, 3. A systematic review of 133 studies found that vaccinations, particularly inactivated vaccines, do not aggravate MS or increase relapse probability 9. Real-world data from 195 MS patients showed no increase in clinical or radiological activity 3-6 months after vaccination 2.

The risk of NOT vaccinating far exceeds any theoretical vaccine risks, especially given that infections themselves are known MS relapse triggers 3, 6.

Related Questions

In a 30‑year‑old male about to start disease‑modifying therapy for multiple sclerosis, should he receive meningococcal and pneumococcal vaccines (since he has not had them since childhood), are they safe, and how long does the protection last?
Will a 30‑year‑old male with multiple sclerosis who undergoes approximately 15–20 peripheral venipunctures (blood draws and short‑term intravenous infusions) per year eventually lose usable veins, and are there studies on individuals who have weekly phlebotomy or donate blood 12 times annually that demonstrate preservation of peripheral veins?
Is amoxicillin appropriate for treating meningococcemia?
What infection control precautions and chemoprophylaxis are recommended for patients with suspected or confirmed bacterial meningitis?
What are the 2024 McDonald criteria for diagnosing multiple sclerosis?
What is the clinical significance of a low‑positive anti‑smooth muscle antibody titer of 1:20?
Does a platelet count of 1.2 × 10⁹/L and ferritin >1000 µg/L in a patient with polycythemia rule out primary polycythemia (polycythemia vera)?
When is elective direct‑current cardioversion indicated?
If blood pressure remains uncontrolled on losartan 50 mg and hydrochlorothiazide 12.5 mg, which medication should be increased?
If mild treatment‑emergent central sleep apnea (TECSA) occurs during auto‑adjusting positive airway pressure (APAP) therapy, is it acceptable to start the therapy and schedule follow‑up in one year, and if pronounced TECSA is observed on APAP, should the therapy be switched to auto‑adjusting bilevel positive airway pressure (auto‑BiPAP)?
What is phakomatosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.